This study found that 1′S-1′-acetoxychavicol acetate from Alpinia galanga inhibits Nox isozymes and suppresses testosterone-induced hair loss in a mouse model of androgenetic alopecia.
3 citations
,
December 2024 in “Biomolecules & Therapeutics” This study found that Tanshinone I and Tanshinone IIA from Salviae Miltiorrhizae Radix inhibited Nox activity heightened by testosterone in a mouse model, reducing H₂O₂ production and cell apoptosis, and reversing testosterone-induced hair growth suppression, suggesting their potential as treatments for androgenetic alopecia.
December 2022 in “Scientific Reports” This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.
15 citations
,
July 2022 in “Nano Research” This study suggests that using cholesterol-free liposomes, specifically PPD-Lip, as a delivery system with dutasteride may enhance the treatment of androgenetic alopecia by promoting hair regrowth in mice models.
August 2025 in “ACS Omega” This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.